Phaseline

Companies › AMAG Pharmaceuticals

AMAG Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 11 registered trials: 4 Phase 3, 4 Phase 2, 2 Phase 1, 1 Phase 4; Neurology, Cardiovascular, Genitourinary, Hematology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ferumoxytol
Iron replacement therapy - iron oxide nanoparticles coated with polyglucose sorbitol carbo
–Phase 3Iron Deficiency Anemia; Chronic Kidney Disease; Iron Deficiency Anemia; Pregnancy Related; Glioblastoma …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04268849FerumoxytolPhase 3Iron Deficiency AnemiaHematologyNov 2025
NCT03893045FerumoxytolPhase 3Iron Deficiency AnemiaHematologyJul 2026
NCT07452250FerumoxytolPhase 2Venous DiseasesCardiovascularAug 2026
NCT03619850FerumoxytolPhase 3Chronic Kidney Disease; Iron Deficiency AnemiaGenitourinaryAug 2026
NCT04278651FerumoxytolPhase 4Pregnancy RelatedHematologyDec 2026
NCT04900792FerumoxytolPhase 1GlioblastomaOncologyDec 2026
NCT05340465FerumoxytolPhase 2PrematurityHematologyJan 2027
NCT06440408FerumoxytolPhase 1Pulmonary Vein StenosisCardiovascularJun 2027
NCT03270059FerumoxytolPhase 2Central Nervous System NeoplasmOncologyDec 2027
NCT07461948FerumoxytolPhase 3GlioblastomaOncologyOct 2028
NCT06483061FerumoxytolPhase 2Epilepsy, Temporal LobeNeurologySep 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Ablative Solutions Mercator MedSystems THPharm Kissei Pharmaceutical Shenzhen Ausa Pharmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.